CTC NORTH GMBH & CO KG

Their core work

CTC North is a Hamburg-based clinical research organization operating as a specialist contributor in multi-site EU clinical trials. Their work centers on the operational and scientific execution of clinical studies — patient recruitment, trial management, and clinical data generation — across neurological and infectious disease indications. In PRECIOUS they contributed to a large randomized controlled trial targeting stroke complications in elderly patients, while in TherVacB they support therapeutic vaccine evaluation for chronic hepatitis B, including a capacity-building dimension in Africa. Their value to consortia lies in bringing clinical trial infrastructure and disease-area expertise rather than leading research programs themselves.

What they specialise in

How they've shifted over time

CTC North entered H2020 through PRECIOUS (2015), where their work was firmly anchored in acute neurology — specifically randomized trials for stroke complication prevention in elderly patients, a classical geriatrics-meets-clinical-research focus. By 2020, with TherVacB, their portfolio shifted entirely to infectious disease: chronic hepatitis B, therapeutic vaccines, and adjuvant science, with an added international dimension through capacity building in Africa. The shift is substantial in therapeutic area but consistent in method — both projects are interventional clinical trials — suggesting the organization is broadening its disease-area coverage while keeping clinical trial execution as their defining competency.

CTC North is moving from disease-specific neurology work toward broader infectious disease and global health trials, suggesting they are positioning as a disease-agnostic clinical research partner available to diverse therapeutic area consortia.

How they like to work

CTC North has participated exclusively as a non-coordinating partner in both projects — they join consortia to deliver clinical expertise rather than to lead them. Despite only two projects, they have accumulated 36 unique consortium partners across 13 countries, which reflects participation in large, multinational clinical networks typical of EU-funded Phase II/III trials. This pattern points to an organization that is well-integrated into European clinical research infrastructure but deliberately operates in a service and execution capacity.

With 36 unique partners across 13 countries from just two projects, CTC North is embedded in broad, multinational clinical research consortia that extend beyond Europe into Africa. Their Hamburg base connects them to Germany's established clinical research infrastructure, while their TherVacB involvement signals ties to international infectious disease networks.

What sets them apart

CTC North is a rare German SME combining clinical trial operations experience across two distinct therapeutic areas — neurology and infectious disease — within the EU research framework. Unlike larger CROs or university hospitals, they offer the flexibility of an SME with demonstrated experience in competitive EU consortium environments. For project coordinators seeking a Hamburg-based clinical partner with proven patient recruitment and trial management capabilities, they bring operational focus without the administrative weight of an academic institution.

Highlights from their portfolio

• PRECIOUS
  CTC North's largest project by far (EUR 384,400, 2015–2022), a multi-year randomized controlled trial addressing a high-burden clinical problem — complications in elderly acute stroke patients — with direct relevance to Europe's aging population.
• TherVacB
  A high-ambition hepatitis B cure program running to 2026 with a global reach including African capacity building, representing CTC North's pivot into infectious disease and therapeutic vaccine trials.